24 July 2012
Russian Nanotechnologies, the state- run technology holding, and Domain Associates, a U.S. venture fund, are investing about $40 million in San Diego-based biopharmaceutical company CoDa Therapeutics.
The deal is the first joint investment between Domain Associates and Rusnano, as the company is known, according to an e-mailed press release. Domain is an investor in CoDa. Rusnano will invest through a subsidiary.
Rusnano teamed up with Domain Associates in March to invest $760 million in U.S. life science companies and build facilities in Russia. The companies plan to invest in about 20 U.S.-based health-care technology companies involved in pharmaceuticals, biotechnology and medical devices, the Moscow-based company said in March.
PrintGrand finale from a veritable stalwart of neuroscience
09 November 2023
Battle of pharma advocates – in search of the ideal migraine therapy
09 November 2023
31 October 2023
01 December 2023
An Indian investor will invest more than 1 billion rubles in a pharmaceutical plant in Nevinnomyssk
01 December 2023
Long COVID study expanded across Europe
30 November 2023
Ethical, Regulatory, and Operational Considerations for Cell and Gene Therapy Research in Children
30 November 2023